Abstract
Objective Cognitive impairment in Parkinson disease (PD) places a high burden on patients and the pathophysiological mechanisms that differentiate patients with cognitive impairment from those without it are still incompletely understood.
Methods We conducted a resting-state seed region-of-interest approach to investigate functional connectivity (FC) of important subdivisions of the caudate nucleus, putamen and thalamus in controls (n=33), cognitively unimpaired subjects (PD-CU, n=33), PD subjects with mild cognitive impairment (PD-MCI, n=22) and subjects with dementia (PDD, n=17). We then investigated how the morphology of these structures differed between groups.
Results PD-CU subjects, compared to controls, displayed increased and decreased FC of caudate, putamen and thalamic subdivisions. PD-MCI subjects demonstrated reduced FC of the mediodorsal thalamus with the paracingulate cortex, compared to PD-CU, and reduced FC of the mediodorsal thalamus with the posterior cingulate cortex compared to PDD. Extensive volumetric and surface-based deflation was found in subjects with dementia.
Conclusions Our research suggests that cognitive impairment and dementia in PD may be associated with a breakdown in FC of the mediodorsal thalamus with para- and posterior cingulate regions of the brain, respectively.
Significance Cognitive impairment and dementia in PD may relate to pathophysiological changes in FC of the mediodorsal thalamus.
Competing Interest Statement
OH has acquired research support (for the institution) from Roche, GE Healthcare, Biogen, AVID Radiopharmaceuticals and Euroimmun. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Biogen and Roche.
Funding Statement
CO-W would like to acknowledge the Australian National University for their funding support via the University Research Scholarship. This project is an initiative of the Swedish BioFINDER Study, of whom DvW and OH are steering committee members, and also the AUSSIE network coordinated by JCLL at the Australian National University Medical School, who self-funds related expenses. DJ reports no funding sources. MW has received consulting fees and honoraria from Actelion Pharmaceuticals and receives royalties from ACER (Australian Council of Educational research) for the NUCOG, a pencil and paper cognitive assessment tool (not used in this study. Work at the SH, DvW and OH research center was supported by the European Research Council, the Swedish Research Council, the Knut and Alice Wallenberg foundation, the Marianne and Marcus Wallenberg foundation, the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s disease) at Lund University, the Swedish Alzheimer Foundation, the Swedish Brain Foundation, The Parkinson foundation of Sweden, The Parkinson Research Foundation, the Skåne University Hospital Foundation, and the Swedish federal government under the ALF agreement. OH has acquired research support (for the institution) from Roche, GE Healthcare, Biogen, AVID Radiopharmaceuticals and Euroimmun. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Biogen and Roche. The authors declare no competing interests. Funding sources had no role in the design and conduct of the study, in the collection, analysis, interpretation of the data or in the preparation, review or approval of the manuscript.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Data Availability
Anonymized data will be shared by request from any qualified investigator for the sole purpose of replicating procedures and results presented in the article and as long as data transfer is in agreement with EU legislation on the general data protection regulation. Data underlying the results described in our manuscript are available from at Attention: Conor Owens-Walton Academic Unit of Psychiatry & Addiction Medicine Australian National University Medical School Building 4, Level 2, Canberra Hospital Woden, A.C.T. 2605 AUSTRALIA or (conor.owens-walton@anu.edu.au)
